Swedish drug development company in clinical phase focused on normalizing the lives for patients with Sickle Cell Disease.
Novel, proprietary treatement for Sickle Cell Disease currently in clinical phase II.
An orphan disease with large unmet medical need.
Recruiting at hospitals in the Netherlands, Jamaica, Turkey, Lebanon, Saudi Arabia, Bahrain and Oman.
The European Patent Office has granted Modus Therapeutics two European patents.
Dr. Öhd joins Modus from Medivir AB, where he was CMO and a member of the company’s Executive Management team
The privately held Swedish biotech Modus Therapeutics is running clinical trials for its sickle cell drug, sevuparin, in the Middle East, where sickle cell disease is prevalent
Sankt Eriksgatan 117,
SE-113 43 Stockholm, Sweden
© 2019 Modus Therapeutics. | All Rights Reserved.